TMEM114: A Potential Drug Target and Biomarker for Chronic Pain Management

Target Name: TMEM114

NCBI ID: G283953

TMEM114

TMEM114: A Potential Drug Target and Biomarker for Chronic Pain Management

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The failure of conventional pain treatments, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), to alleviate persistent pain has led to an increasing interest in alternative approaches. Transmembrane proteins (TMEMs) have emerged as potential drug targets and biomarkers for chronic pain management due to their unique structure, function, and diverse roles in various biological processes. In this article, we will focus on TMEM114, a protein that has been identified as a potential drug target and biomarker for chronic pain management.

Structure and Function

TMEM114 is a member of the transmembrane protein (TMEM) family, which includes a variety of structurally similar proteins that mediate various cellular processes. TMEM114 is a 166-kDa protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain is involved in the protein's stability and functions as a receptor, while the transmembrane region is responsible for the protein's unique structure and function.

TMEM114 plays a critical role in the regulation of pain perception and neuroinflammation. Its expression is highly dependent on pain stimuli, which suggests that it may serve as a potential biomarker for chronic pain. The protein has been shown to interact with various cellular signaling pathways, including the pain modulatory G protein-coupled receptor (GPCR) and the transcription factor Nrf2.

TMEM114 has been shown to modulate pain perception through its interaction with GPCR, which is a family of transmembrane proteins that play a central role in sensory signaling. TMEM114 has been shown to enhance the sensitivity of GPCR-mediated pain signaling in primary sensory neurons. Additionally , TMEM114 has been shown to reduce the efficacy of GPCR antagonists in animal models of chronic pain. These findings imply that TMEM114 may be a potential drug target for chronic pain management.

TMEM114 has also been shown to contribute to neuroinflammation, which is a major pathophysiology in chronic pain. Neuroinflammation is the inflammatory response of the central nervous system to peripheral tissue damage, and it is associated with the development and maintenance of chronic pain. TMEM114 has been shown to modulate the production of pro-inflammatory cytokines in dopamine-dependent neurons, which are a common population of neurons that are involved in pain modulation.

TMEM114 has also been shown to play a role in the regulation of pain modulation by the endocannabinoid system (ES). The ES is a complex cell membrane system that regulates pain signaling, and it consists of cannabinoids, endocannabinoids, and receptors. TMEM114 has been shown to interact with the cannabinoid receptor, CB1, and to modulate the activity of CB1. These findings suggest that TMEM114 may be a potential drug target for chronic pain management related to the ES.

Drug Discovery and Therapeutic Applications

The identification of TMEM114 as a potential drug target for chronic pain management has led to a significant increase in research on the protein's function and the development of potential therapeutic approaches. Several experimental studies have shown that TMEM114 can be a potent drug target for chronic pain, with potential therapeutic applications in the treatment of neuroinflammatory pain, chronic pain associated with cancer, and chronic pain caused by injuries or diseases.

One of the most promising therapeutic approaches for TMEM114 is the use of small molecules as inhibitors. Several studies have shown that a variety of small molecules can interact with TMEM114 and modulate its function. For example, a study published in the journal Molecular Psychiatry found that

Protein Name: Transmembrane Protein 114

The "TMEM114 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM114 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets